Go to Dr. Arun K. Kalra Resume Go to Dr. Henry Tsai Resume Go to Dr. Varun Gupta Resume Go to Dr. Iliana Popescu Resume
VARUN GUPTA, M.D.
 
Office:
Desert Cancer Care, Inc.
39000 Bob Hope Dr.,
Eisenhower Medical Center
Uihlein Bldg., Ste. 201
Rancho Mirage, CA  92270
 
Affiliating Institutions :
Eisenhower Medical Center
39000 Bob Hope Dr.,
Rancho Mirage, CA  92270
 
Education:
 
 
MBBS:
1987-1992 
Medical School and Internship
Dayanand Medical College and Hospital
Punjab University, India
 
MD:
1994-1997
Internal Medicine Residency
Long Island College Hospital
State University of New York
 
Fellowship:
1994-1997
Medical Oncology Fellowship
North Shore University Hospital
NYU School of Medicine
 
Board Certification:
Diplomate Medical Oncology, American Board of Internal Medicine
 
Interests:
Particular interest in Lung, Prostate Cancers and GI Cancers.
 
Positions and Appointments:
 
 
2005 - Current
Desert Cancer Care, Inc.
Uihlein Bldg, #201
Eisenhower Medical Center Campus
39700 Bob Hope Drive
Rancho Mirage, CA 92270
 
2004 - 2005
Cancer and Blood Institute of the Desert,
Rancho Mirage, CA  92270
 
2000 - 2004
Medical Oncology
Morongo Medical Group
 
Licenses:
California
South Carolina
Florida
 
Honors and Awards:
. Chair, Section of Oncology
   Eisenhower Medical Center
. Chief Fellow, Hematology/Oncology
   North Shore Hospital, NY
.  Assistant Chief Resident Department of  Medicine
   Long Island College Hospital, NY
.  Awarded Best Graduating Resident
   Department of Medicine Long Island  College Hospital, NY
.  National Scholarship through Medical School
 
Memberships:
. American College of Physicians
. American Society of Clinical Oncology
 
Publications:
 
 
  • Radiation therapy in cancer patients 80 years of age and older Am J Clin Oncol 2000 Oct; 23(5): 526-30
  • Liver dysfunction after high-dose chemotherapy and role of histologic diagnosis Poster presented at ASCO 2000.
  • Novel chemotherapy agents, The Chemotherapy Source Book,  editor M. Perry, 2001.
  • Letter to Editors:  Harrison’s Principles of Internal Medicine.  Comment on CDC Classification of AIDS
 
Research Experience:
 
 
ASCO 2010 Meeting
A phase ll study of a modified pegylated liposomal doxorubicin (PLD), bortezomid, and dexamethasone regimen for patients with previously untreated multiple myeloma (MM).
2008
Sub-Investigator - Novartis Pharmaceuticals Corp: A prospective, Randomized, Multi-Center, 3 arm of the continued efficacy and  safety of Zometa in patients with documented bone metastases from Breast cancer.  Protocol #CZOL446E2352
2008
Principal-Investigator - Amgen Protocol# 20050154:  Phase 2,
Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy-Induced Thrombocytopenia In Subject with Advanced Non-Small Cell
Lung Cancer Already Receiving Gemcitabine and Platinum.
2008
Sub-Investigator – GPC Biotech Inc.: Protocol # SAT3-06-04 Expanded Access  Study of Satraplatin Plus Prednisone in Patients with Hormone Refratory Prostate Cancer Previously Treated with Unlimited Cytotoxic Chemotherapy.
2008
Principal-Investigator for Millennium Pharma., : Protocol # C05009:
Phase IIIB, randomized study of three treatment regimens in subjects with previously untreated Multpile Myeloma who are not considered candidates High Dose Chemotherapy and Autologous Stem Cell Transplatation.  Velcade, Thalomide & Dexamethasone (VTD) vs. Velcade and Dexamethasone (VD)
Vs. Velcade, Melphalan, and Prednisone (VMP).
2008
Sub-Investigator – NSABP-B-42:  A Clinical Trial to Determine the Efficacy o Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Follow by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.
2008